Use of COVID-19 Convalescent Plasma for Treatment of Symptomatic SARS-CoV-2 Infection at a Children’s Hospital: A Contribution to a Still Inadequate Body of Evidence

Data on COVID-19 convalescent plasma (CCP) safety and efficacy in children and young adults are limited. This single-center prospective, open-label trial evaluates CCP safety, neutralizing antibody kinetics, and outcomes in children and young adults with moderate/severe COVID-19 (April 2020–March 20...

Descripción completa

Detalles Bibliográficos
Autores principales: Arrieta, Antonio, Galvis, Alvaro E., Osborne, Stephanie, Morphew, Tricia, Imfeld, Karen, Enriquez, Claudia, Hoang, Janet, Swearingen, Marcia, Nieves, Delma J., Ashouri, Negar, Singh, Jasjit, Nugent, Diane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955755/
https://www.ncbi.nlm.nih.gov/pubmed/36832478
http://dx.doi.org/10.3390/children10020350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955755/
https://www.ncbi.nlm.nih.gov/pubmed/36832478
http://dx.doi.org/10.3390/children10020350

Ejemplares similares